Corrigendum: Genome Editing for CNS Disorders

Fábio Duarte^{1

2}, Nicole Déglon^{1

2}

Affiliations

¹ Laboratory of Neurotherapies and NeuroModulation, Department of Clinical Neurosciences, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
² Laboratory of Neurotherapies and NeuroModulation, Neuroscience Research Center, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.

Published Erratum

Fábio Duarte et al. Front Neurosci. 2021.

. 2021 May 26:15:698879.

doi: 10.3389/fnins.2021.698879. eCollection 2021.

Fábio Duarte^{1

2}, Nicole Déglon^{1

2}

¹ Laboratory of Neurotherapies and NeuroModulation, Department of Clinical Neurosciences, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
² Laboratory of Neurotherapies and NeuroModulation, Neuroscience Research Center, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.

Abstract

[This corrects the article DOI: 10.3389/fnins.2020.579062.].

Keywords: CNS; CRISPR/Cas; TALEs; ZFs; genome editing.

Genome Editing for CNS Disorders.
Duarte F, Déglon N. Duarte F, et al. Front Neurosci. 2020 Oct 22;14:579062. doi: 10.3389/fnins.2020.579062. eCollection 2020. Front Neurosci. 2020. PMID: 33192264 Free PMC article. Review.

1. Das U., Wang L., Ganguly A., Saikia J. M., Wagner S. L., Koo E. H., et al. . (2016). Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat. Neurosci. 19, 55–64. 10.1038/nn.4188 - DOI - PMC - PubMed
1. Dos Santos Picanco L. C., Ozela P. F., de Fatima de Brito Brito M., Pinheiro A. A., Padilha E. C., Braga F. S., et al. . (2018). Alzheimer's disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Curr. Med. Chem. 25, 3141–3159. 10.2174/0929867323666161213101126 - DOI - PubMed
1. György B., Lööv C., Zaborowski M. P., Takeda S., Kleinstiver B. P., Commins C., et al. . (2018). CRISPR/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer's disease. Mol. Ther. Nucleic Acids 11, 429–440. 10.1016/j.omtn.2018.03.007 - DOI - PMC - PubMed
1. Koo E. H., Squazzo S. L. (1994). Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386–17389. - PubMed
1. Park H., Oh J., Shim G., Cho B., Chang Y., Kim S., et al. . (2019). In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease. Nat. Neurosci. 22, 524–528. 10.1038/s41593-019-0352-0 - DOI - PubMed